Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (81-90 of 227) with videos related to

Pageof 23
Sort By:
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
The Oncologist|January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 TrialKathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Genitourinary Cancer|May 15, 2018
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell CarcinomaXin Gao, Opeyemi Jegede, Connor Gray, et al.
Frontiers in Oncology|February 27, 2023
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanomaAnn W Silk, Brendan Curti, Jennifer Bryan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
European Urology Focus|July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaGuillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
Urology|March 13, 2010
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyMichael M Vickers, Toni K Choueiri, Miranda Rogers, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinomaRana R McKay, Michael Serzan, Wanling Xie, et al.
Pageof 23

Showing results (81-90 of 227) with videos related to

Sort By:
Pageof 23
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
The Oncologist|January 23, 2024
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 TrialKathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Genitourinary Cancer|May 15, 2018
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell CarcinomaXin Gao, Opeyemi Jegede, Connor Gray, et al.
Frontiers in Oncology|February 27, 2023
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanomaAnn W Silk, Brendan Curti, Jennifer Bryan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
European Urology Focus|July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaGuillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
Urology|March 13, 2010
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyMichael M Vickers, Toni K Choueiri, Miranda Rogers, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinomaRana R McKay, Michael Serzan, Wanling Xie, et al.
Pageof 23